Delcath Systems up on CHEMOSAT data presented at ASCO
May 29 2015, 10:23 ET | About: Delcath Systems, Inc. (DCTH) | By: Douglas W. House, SA News Editor [Contact this editor with comments or a news tip]
Delcath Systems (DCTH +32.8%) moves up on a 10x surge in volume in response to an online abstract presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
The abstract, "Single Centre Experience of Chemosaturation Percutaneous Hepatic Perfusion in the Treatment of Metastatic Uveal Melanoma," relates to data from 20 patients with ocular melanoma who each received 1-3 treatments with the company's percutaneous hepatic perfusion therapy CHEMOSAT. Two patients showed stable disease for more than three months, 13 had a partial response in the liver and two had a complete response. Nine deaths from cancer progression occurred after a median of 264 days from the date of the first procedure. 11 patients remain alive after a median of 280 days with one complete response ongoing after more than one year. From the diagnosis of liver metastases, 11 patients have survived one year and three for more than two years.
Uveal melanoma, also known as ocular melanoma, is a rare cancer of the eye with a very poor prognosis. Half of the patients develop metastases, the vast majority (90%) in the liver. Mean survival is only six months. The one-year survival rate is 15 - 20%.
CHEMOSAT is high dose chemotherapy (melphalan) that is directly perfused into the liver via a catheter. It is CE Mark-approved in Europe but still experimental in the U.S.
